Your Model Contract Is About to Change Owners
The counterparty across the table still wants growth more than margin, and that stops being true the moment public shareholders own the ask.
What the reported multiple is actually pricing
A reported $2 trillion puts Anthropic at roughly 17x forward revenue against backers' projection of a $120 billion run-rate exiting 2026. That projection is an investor number, not a filed figure, per Morning Brew. Some backers argue $3 trillion is the honest mark, since Palantir and Nebius trade near 55x. A reasonable skeptic would say the exact multiple is the least interesting part of this, and the skeptic is right. What matters downstream is that the entire AI-adjacent capital market becomes correlated to one private company's revenue ramp holding, which means part of a 2027 cost of capital now rests on a figure nobody outside the cap table can see.
The fine print that reaches customer commitments
Three facts sit underneath the valuation and none of them are about price. The Trump administration temporarily export-controlled Anthropic's most powerful models in June, which spooked customers and measurably slowed growth. Anthropic is suing the federal government over the Pentagon's designation of its products as a supply-chain risk. And it is reportedly spending $6B on Decart to cut training costs and design its own chips. Read together, they describe a vendor whose top capability has already been interrupted once by government action. A supply-chain-risk label does not stop at the vendor: it travels into downstream procurement reviews, where a buyer ends up explaining someone else's litigation.
| Dimension | Anthropic | OpenAI | Alphabet |
|---|---|---|---|
| Price position | 2.5x premium on flagship | Cost anchor | Structurally lowest via own silicon |
| Regulatory exposure | High — export controls, risk designation, active litigation | Moderate | Low on supply chain, high on antitrust |
| Go-to-market stability | Pre-listing, acquisition-active | Revenue chief exited inside a year | Stable |
| What it means for you | Best output, real continuity risk | Best price anchor right now | Best hedge if cost beats quality |
Why the window is about one quarter wide
The tradeoff here is timing, not vendor selection. Pre-listing labs optimize revenue growth and discount to win logos. Newly public labs defending a high multiple optimize gross margin. Every rate card in force today was written by a counterparty in the first mode that will shortly be operating in the second. OpenAI's go-to-market is loose at exactly the same moment, with its revenue chief out in under a year amid wider executive churn, which makes it the cleanest price anchor available before either listing. Anthropic is meanwhile extending upward into reusable, shareable agent scaffolding, so switching costs deepen on precisely the timeline its pricing posture hardens.
The best model on the market is now the one with the most political exposure and the least remaining reason to discount.
The move that survives either outcome
Portability is the cheapest insurance available: one production workload switchable between two providers inside 72 hours, with the quality delta measured and written down. That converts a vendor's pricing power into buyer leverage without launching a migration program. Then the paper, which matters more than the architecture: regulatory force-majeure coverage for model restrictions, substitution rights, and a declining rate card rather than a flat one. One caution against overcorrecting. If inference economics improve materially over the next 18–24 months as frontier labs internalize silicon, long fixed committed spend signed this quarter locks in today's worst price for years. The purchase is continuity and flexibility, not term length.
What to do
Reopen Anthropic and OpenAI commercial terms this month, demanding regulatory force-majeure coverage for model restrictions, substitution rights, and a declining rate card.
Fund one production workload switchable between two model providers inside 72 hours by quarter end, with the measured quality delta documented for the risk committee.
Commission a written map of every account where a vendor's federal supply-chain-risk designation affects eligibility or triggers disclosure, delivered to the risk committee this quarter.